U.S. markets closed
  • S&P Futures

    4,242.25
    +10.75 (+0.25%)
     
  • Dow Futures

    33,868.00
    +109.00 (+0.32%)
     
  • Nasdaq Futures

    14,297.50
    +34.50 (+0.24%)
     
  • Russell 2000 Futures

    2,309.30
    +9.00 (+0.39%)
     
  • Crude Oil

    73.12
    +0.04 (+0.05%)
     
  • Gold

    1,775.30
    -8.10 (-0.45%)
     
  • Silver

    25.94
    -0.17 (-0.64%)
     
  • EUR/USD

    1.1927
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • Vix

    16.32
    -0.34 (-2.04%)
     
  • GBP/USD

    1.3962
    -0.0002 (-0.01%)
     
  • USD/JPY

    111.0150
    +0.0530 (+0.05%)
     
  • BTC-USD

    32,550.54
    -1,594.80 (-4.67%)
     
  • CMC Crypto 200

    781.32
    -28.88 (-3.56%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,918.21
    +43.32 (+0.15%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CYDY, RIDE and FGEN

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / May 12, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

CytoDyn Inc. (OTCMKT:CYDY)
Class Period: March 27, 2020 - March 9, 2021
Lead Plaintiff Deadline: May 17, 2021

According to the complaint, CytoDyn Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: CytoDyn securities were actively traded over the counter (OTC) in the United States. While the exact number of Class members is unknown to Plaintiff at this time and can be ascertained only through appropriate discovery, Plaintiff believes that there are hundreds or thousands of members in the proposed Class. Record owners and other members of the Class may be identified from records maintained by CytoDyn or its transfer agent and/or OTC Markets and may be notified of the pendency of this action by mail, using the form of notice similar to that customarily used in securities class actions.

Learn about your recoverable losses in CYDY: http://www.kleinstocklaw.com/pslra-1/cytodyn-inc-loss-submission-form?id=15748&from=1

Lordstown Motors Corp (NASDAQ:RIDE)
Class Period: August 3, 2020 - March 24, 2021
Lead Plaintiff Deadline: May 17, 2021

Lordstown Motors Corp allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's purported pre-orders were non-binding; (ii) many of the would-be customers who made these purported pre-orders lacked the means to make such purchases and/or would not have credible demand for Lordstown's Endurance; (iii) Lordstown is not and has not been "on track" to commence production of the Endurance in September 2021; (iv) the first test run of the Endurance led to the vehicle bursting into flames within 10 minutes; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in RIDE: http://www.kleinstocklaw.com/pslra-1/lordstown-motors-corp-loss-submission-form?id=15748&from=1

FibroGen, Inc. (NASDAQ:FGEN)
Class Period: October 18, 2017 - April 6, 2021
Lead Plaintiff Deadline: June 11, 2021

The FGEN lawsuit alleges that FibroGen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in FGEN: http://www.kleinstocklaw.com/pslra-1/fibrogen-inc-loss-submission-form?id=15748&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/646748/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-CYDY-RIDE-and-FGEN